A Phase III Study Comparing Irinotecan, Cisplatin and Etoposide (PEI) with Nogitecan for the Treatment of Relapsed Small-Cell Lung Cancer (JCOG0605).

Trial Profile

A Phase III Study Comparing Irinotecan, Cisplatin and Etoposide (PEI) with Nogitecan for the Treatment of Relapsed Small-Cell Lung Cancer (JCOG0605).

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2016

At a glance

  • Drugs Cisplatin (Primary) ; Etoposide (Primary) ; Irinotecan (Primary) ; Topotecan
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jun 2016 Primary endpoint has been met. (Overall survival), as per results published in the Lancet Oncology.
    • 13 Jun 2016 Status changed from active, no longer recruiting to completed, as per results published in the Lancet Oncology.
    • 13 Jun 2016 Results published in the Lancet Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top